What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Laura J. Esserman focuses on Breast cancer, Cancer, Internal medicine, Oncology and Neoadjuvant therapy.
Her Breast cancer research includes themes of Magnetic resonance imaging, Surgery, Chemotherapy and Pathology.
Her biological study spans a wide range of topics, including Mastectomy and Cohort.
The concepts of her Cancer study are interwoven with issues in Clinical trial, Disease, Lymph node and Carcinoma.
As part of one scientific family, Laura J. Esserman deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gynecology, and often Taxane, Anthracycline and Gastroenterology.
Her Oncology study incorporates themes from Aromatase inhibitor, Prostate, Incidence, Proportional hazards model and Prostate cancer.
Her most cited work include:
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. (1070 citations)
- Whole-genome analysis informs breast cancer response to aromatase inhibition (782 citations)
- Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial (563 citations)
What are the main themes of her work throughout her whole career to date?
Her scientific interests lie mostly in Breast cancer, Internal medicine, Oncology, Cancer and Surgery.
Her Breast cancer research integrates issues from Clinical trial, Radiology and Chemotherapy.
Her studies link Gynecology with Internal medicine.
Her Oncology study integrates concerns from other disciplines, such as Proportional hazards model, MammaPrint, Disease and Trastuzumab.
Her Cancer research incorporates elements of Cancer research and Pathology.
Laura J. Esserman works mostly in the field of Surgery, limiting it down to concerns involving Mastectomy and, occasionally, Implant.
She most often published in these fields:
- Breast cancer (64.35%)
- Internal medicine (40.64%)
- Oncology (38.50%)
What were the highlights of her more recent work (between 2018-2021)?
- Breast cancer (64.35%)
- Internal medicine (40.64%)
- Oncology (38.50%)
In recent papers she was focusing on the following fields of study:
Laura J. Esserman mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy.
Laura J. Esserman is involved in the study of Breast cancer that focuses on Breast cancer screening in particular.
Her research in Oncology intersects with topics in MammaPrint, Clinical endpoint, Proportional hazards model, Hazard ratio and Cohort.
The concepts of her Cancer study are interwoven with issues in Biomarker and Confidence interval.
In her study, which falls under the umbrella issue of Neoadjuvant therapy, Recurrence free survival is strongly linked to Radiology.
She interconnects Psychological intervention and Quality of life in the investigation of issues within Clinical trial.
Between 2018 and 2021, her most popular works were:
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial (90 citations)
- The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)
- Adaptive platform trials: definition, design, conduct and reporting considerations. (64 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Her primary areas of investigation include Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy.
The various areas that Laura J. Esserman examines in her Breast cancer study include Biomarker, Area under the curve, Chemotherapy, Magnetic resonance imaging and Stage.
Her studies deal with areas such as Letrozole, Tamoxifen, Estrogen receptor, Hazard ratio and Triple-negative breast cancer as well as Oncology.
She has researched Cancer in several fields, including Family medicine and Confidence interval.
Her Neoadjuvant therapy research is multidisciplinary, incorporating elements of Clinical endpoint, Clinical trial, Randomized controlled trial, Hormone receptor and Proportional hazards model.
Her biological study deals with issues like Protein expression, which deal with fields such as Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
